> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Developing Clostridioides Difficile Infection
- URL: https://www.fdaweb.com/guide-on-developing-clostridioides-difficile-infection/
- Published: 2026-05-11T12:00:00.000Z
- Updated: 2026-09-14T13:38:58.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161123

FDA has issued [updated guidance](https://www.fda.gov/media/162692/download?ref=fdaweb.com) for companies developing therapies to treat, prevent or reduce recurrence of *Clostridioides difficile* infection (CDI), outlining clinical trial expectations as the agency seeks to encourage new options for a disease that continues to cause serious illness and frequent relapse. The guidance covers development programs for drugs intended to treat active CDI, prevent infection in high-risk patients, or reduce the risk of recurrence after successful treatment of an initial episode. FDA says the document applies to both small-molecule drugs and therapeutic biologics regulated by the CDER, though it excludes products such as fecal microbiota transplantation therapies, probiotics, vaccines and live biotherapeutic products.

FDA describes CDI as a toxin-mediated disease caused by *Clostridioides difficile*, an anaerobic spore-forming bacterium that produces toxins responsible for intestinal inflammation and severe diarrhea. Certain strains, including the hypervirulent 027/BI/NAP1 lineage, also produce a binary toxin associated with more severe disease.

Under the guidance, FDA recommends that pivotal trials for CDI therapies generally be randomized, double-blind and controlled. Active comparators are recommended for treatment studies, while placebo-controlled designs may be acceptable in prevention or recurrence-reduction trials.

For investigational therapies intended to treat active infection, FDA says sponsors may pursue either superiority or noninferiority study designs compared with standard-of-care treatment. However, the agency said superiority designs are preferred for drugs intended to reduce recurrence or prevent CDI altogether unless sponsors can adequately justify a noninferiority margin.

FDA also outlines recommended clinical trial time points, including an end-of-treatment assessment, a test-of-cure visit two days after therapy completion and a late follow-up evaluation at least four weeks after treatment ends.

The guidance emphasizes that efficacy assessments should focus on clinically meaningful outcomes rather than microbiological testing alone. For treatment trials, FDA recommends a primary endpoint based on survival and resolution of diarrhea without the need for additional CDI therapy through the test-of-cure visit. The agency also identified sustained clinical response — defined as remaining alive and recurrence-free for at least four weeks after treatment — as an important secondary endpoint.

For prevention trials, FDA says the primary endpoint should measure whether participants develop CDI during a predefined follow-up period.

The agency advises sponsors to discuss overall development strategies with FDA early in clinical development and said, in some cases, a single adequate and well-controlled study supported by confirmatory evidence may be sufficient to establish effectiveness.